Featured NeWS

Filament Health Enters Into Exclusive License Agreement With University Of Alabama at Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder

Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder

Just one single dose of ‘magic mushrooms’ could relieve depression for 5 years, researchers find

New York Post

Voluntary Delisting: Summary & Explanation

No items found.

Press Releases

Filament Health Enters Into Exclusive License Agreement With University Of Alabama at Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder

Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder

Filament Health Announces Transition From OTCQB To OTC Pink Limited

recent news

Just one single dose of ‘magic mushrooms’ could relieve depression for 5 years, researchers find

New York Post

These patients are considering MAiD. They say Canada has made it harder to access magic mushrooms — a treatment giving them reason to live

The Toronto Star

November 13, 2024

Innovative trial will use psilocybin to target relapse in opioid addiction

Imperial College London

October 18, 2024

events and Podcasts

Causes or Cures Podcast: Natural vs Synthetic Psychedelics, Does It Matter?

The Bio Report Podcast: Extracting the Benefits of Psychedelics

School For Startups Podcast: Legal Psychedelics

blog

Voluntary Delisting: Summary & Explanation

Botanical Psilocybin & Alcohol Use Disorder: A Promising Treatment

Psychedelics & Substance Use Disorders: An Innovative Approach to a Growing Crisis

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Preferences Deny Accept